Trusted Resources: News & Events
Latest announcements and gatherings
Matthew Porteus awarded grant for sickle cell anemia work
The California Institute for Regenerative Medicine has awarded MATTHEW PORTEUS, associate professor of pediatrics, a grant of $5.2 million to lay the groundwork for a clinical trial of a possible treatment for sickle cell disease.
Porteus has shown that he can take human blood stem cells with the gene defect that causes sickle cell disease and use gene-editing tools to repair the faulty gene. He also showed that he could successfully transplant those repaired blood stem cells into mice.
“We are extremely excited that, with CIRM support, we may be able to use gene correction to treat this terrible disease,” Porteus said.
+myBinderRelated Content
-
Music therapy helps relieve pain in adults with sickle cell disease, pilot trial suggestsMusic therapy can help ease pain in ad...
-
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease DesignationThe U.S. Food and Drug Administration (F...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Gene-Editing Treatment Shows Promise for Sickle Cell DiseaseScientists are seeing promising early re...
-
Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (...BACKGROUND: Little is known about red b...
-
The clinical and biochemical effects of treatment with omega-3 fatty acids in patients with homozygous sickle cell d...Background: Chronic inflammation, coagu...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.